Skip to main content
SpringerLink
Log in

Systemic Therapy

  • Chapter
Liver Metastases

  • 85 Accesses

Abstract

Most neoplastic diseases will develop liver metastases along their progression. Liver metastases represent a major problem among cancer patients, their high incidence only being exceeded by that of nodal involvement. The proportion of patients with metastatic liver disease has increased in the latest years, as a consequence of technical improvements in diagnostic instruments (e.g. Computed tomography scans, ultrasonography, MRI, markers, nuclear medicine).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Heidelberg C, Chaudhuri NK. Nature, 1957; 179:663

    Article  Google Scholar 

  2. Heidelberg C. Pyrimidine and pyrimidine nucleoside antimetabolites. In Cancer Medicine, Holland J,F, Frei E, (eds), 1973; 768. Philadelphia, Lea & Febiger.

    Google Scholar 

  3. Mandel HG. Incorporation of 5-fluorouracil into RNA and its molecular consequences. Prog Mol Subcell Bioi 1969; 1:82-l35

    CAS  Google Scholar 

  4. Schuetz JD, Collins JM, Wallace HJ Alteration of the secondary structure of newly synthesized DNA from murine bone marrow cells by 5-fluorouracil. Cancer Res 1986; 46:119–123

    Article  PubMed  CAS  Google Scholar 

  5. Lokich JJ, Ahlgren JD, Gullo JJ. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7:425–432

    PubMed  CAS  Google Scholar 

  6. Weinerman B, Shah A, Fields A. Systemic infusion versus bolus chemotherapy in measurable colorectal cancer. Am J Clin Uncol 1992; 15:518–523

    Article  CAS  Google Scholar 

  7. Rougier P, Paillot B, Lapplanche A. End result of multicenter randomized trial comparing 5-FU in continous systemic infusion to bolus administration in measurable metastatic colorectal cancer. Proc ASCO 1992; 11:465

    Google Scholar 

  8. Hansen R, Ryan L, Anderson T, Quebberman E, Haller D. A phase III trial of bolus 5-FU versus protracted infusion 5- FU cisplatin in metastatic colorectal cancer. An Eastern Cooperative Oncology Group study (EST 2286). Proc ASCO 1992; 11:499

    Google Scholar 

  9. Leichman CG, Fleming TR, Muggia FM. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.] Clin Oncol 1995; 13:1303–1311

    PubMed  CAS  Google Scholar 

  10. Ardalan B, Chua L, Tian EM. A phase II study of weekly 24- hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma.J Clin Oncol 1991; 9(4):625–630

    PubMed  CAS  Google Scholar 

  11. Weh HJ, Wilke HJ, Dierlamm J. Weekly therapy with folinic acid and high-dose 5-fluorouracil24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 1994; 5:233–237

    CAS  Google Scholar 

  12. Jaeger E, Klein O, Wachtter B, Muller B, Braun U, Knuth A. A second line treatment with high dose 5-fluorouracil and folinic acid in advanced colorectal cancer refractory to standard- dose 5-fluorouracil treatment. Oncology 1995; 52:470–473.

    Article  CAS  Google Scholar 

  13. Loeffler, Personal comunication, 1995

    Google Scholar 

  14. Lorenz, Personal comunication, 1996

    Google Scholar 

  15. Petrelli N, Herrera L., Rustum Y. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.J Clin Oncol 1987; 5:1559–1565

    PubMed  CAS  Google Scholar 

  16. Valone FH, Friedman MA, Wittlinger PS. Treatment of patients with advanced colorectal cancer with fluorouracil alone, high dose leucovorin plus fluorouracil, or sequential, methotrexate, fluorouracil and leucovorin: a randomized trial of the Northern California Oncology Group.J Clin Oncol 1989; 7:1427–1436

    PubMed  CAS  Google Scholar 

  17. Di Costanzo F, Bartolucci R, Sofra M. 5-fluorouracil alone vs. high dose folinic acid and 5-FU in advanced colorectal cancer. A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Proc ASCO 1989; 8:410.

    Google Scholar 

  18. Labianca R, Pancera G, Aitini E. Folinic acid + 5- fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of GISCAD (Italian Group for the Study of Digestive Tract Cancer) Ann Oncol 1991; 2:673–679

    PubMed  CAS  Google Scholar 

  19. Nobile MT, Vidili MG, Sobrero A. 5-fluorouracil alone or combined with high-dose folinic acid in advanced colorectal cancer patients. Proc ASCO 1988; 7:371

    Google Scholar 

  20. Erlichman C, Fine S, Wong A. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma.J Clin Oncol 1988; 6:469–475

    PubMed  CAS  Google Scholar 

  21. Doroshow JH, Multauf P, Leong L et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patient previously unexposed to chemotherapy.J Clin Oncol 1990; 8:491–501.

    PubMed  CAS  Google Scholar 

  22. Petrelli N.Douglass HO.The modulation of fluorouracil and leucovorin in metastatic colorectal cancer: A prospective randomized phase III trial.J Clin Oncol 1989; 7:1419–1426.

    PubMed  CAS  Google Scholar 

  23. Cricca A, Martoni A, Guaraldi M. Randomized clinical trial of 5-FU and folinic acid in advanced gastrointestinal cancers. Proc ESMO 1988; 13:427

    Google Scholar 

  24. Po on MA, O’Connell MJ, Moertel CG. Biochemical modulation of fluorouracil. Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.J.Clin Oncol 1989; 7:1427–1436.

    Google Scholar 

  25. Advanced Colorectal Cancer Metaanalysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer.J Clin Oncol 1992; 10:869–903.

    Google Scholar 

  26. Buroker TR, O’Connell MJ, Wieand HS. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12:14–20.

    Google Scholar 

  27. Jaeger E, Klein 0, Bernhard H: Weekly high-dose folinic acid (FA)/5-fluorouracil (FU) versus low-dose FA/FU in advanced colorectal cancer. Results of a randomized multicentric trial. Proc ASCO 1994; 13:556.

    Google Scholar 

  28. Poon MA, O’Connell MJ, Wieand HS. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer.J Clin Oncol 1991; 9:1967–1972.

    PubMed  CAS  Google Scholar 

  29. Valsecchi R, Labianca R, Cascinu S. High-dose versus lowdose L-leucovorin as a modulator of 5 days 5-fluorouracil in advanced colorectal cancer: a GISCAD phase III study. Proc ASCO 1995; 14:457.

    Google Scholar 

  30. DeGramont A, Bosset JF, Milan C. A prospective randomized trial comparing 5-FU bolus with low-dose folinic acid (FUFOLId) and 5-FU bolus plus continuous infusion with high-dose folinic acid (LV5FU2) for advanced colorectal cancer. Proc ASCO 1995; 14:455.

    Google Scholar 

  31. Marsh JC, Bertino JR, Katz KH. The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer.J Clin Oncol 1991; 9:371–380.

    PubMed  CAS  Google Scholar 

  32. Hermann R, Knuth A, Kleeberg U. Sequential methotrexate and 5-fluorouracil (FU) vs. FU alone in metastatic colorectal cancer. Ann Oncol 1992; 3:539–543.

    Google Scholar 

  33. Machiavelli M, Leone BA, Romero A. Advanced colorectal carcinoma: a prospective randomized trial of sequential methotrexate, 5 fluorouracil, and leucovorin versus 5- fluorouracil alone. Am J Clin Oncol 1991; 14:211–217.

    PubMed  CAS  Google Scholar 

  34. Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Superiority of sequential methotrexate, fluorouracil and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma. A randomized trial.J Clin Oncol 1989; 7:1437–1446.

    Google Scholar 

  35. Piedbois P, Buyse M, Blijham G et al. Meta-analysis of randomized trial testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer.J Clin Oncol 1994; 12:960–969.

    Google Scholar 

  36. Wadler S, Wiernik PM. Clinical update on the role of fluorouracil and recombinant interferon alpha-2a in the treatment of colorectal carcinoma. Semin Oncol 1990; 17:16.

    PubMed  CAS  Google Scholar 

  37. Fornasiero A, Daniele O, Ghiotto C. Alpha-2 interferon and 5-fluorouracil in advanced colorectal cancer. Tumori 1990; 76:385–389.

    PubMed  CAS  Google Scholar 

  38. Kemeny N, Younes A, Seiter K, et al. Interferon alfa-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity. Cancer 1990; 66:2470–2475.

    Article  PubMed  CAS  Google Scholar 

  39. Pazdur R, Ajani JA, Patt YZ, Winn R, Jackson D, Shepard B.Phase II study of fluorouracil and recombinant interferon alpha-2a in previously untreated advanced colorectal carcinoma.J Clin 1990; 8:2027–2031.

    PubMed  CAS  Google Scholar 

  40. Wadler S, Goldman M, Lyver A, Wiernik PH. Phase I trial of 5-fluorouracil and recombinant alpha (2a)-interferon in patients with advanced colorectal carcinoma. Cancer Res 1990; 50:2056–2059.

    PubMed  CAS  Google Scholar 

  41. Wadler S, Wiernik PH. Clinical update on the role of fluorouracil and recombinant interferon alpha-2a in the treatment of colorectal carcinoma. Semin Oneal 1990; 17(Suppll):16–21.

    CAS  Google Scholar 

  42. Wadler S, Lembersky B, Atkins M. Kirkwood I, Petrelli N. Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group Study. J Clin Oneal 1991; 9:1806–1810.

    CAS  Google Scholar 

  43. Ajani JA, Rios AH, Ende K. Phase I and II studies of the combination of recombinant human interferon gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. J Bioi Response Mod 1989; 8:140–146.

    CAS  Google Scholar 

  44. Huberman M, Mc Clay E, Atkins M. Phase II trial of 5- fluorouracil (5-FU) and recombinant interferon alpha 2-a (IFN) in advanced colorectal cancer. Proc ASCO 1991; 10:478.

    Google Scholar 

  45. Donillard JY, Leborgne I, Danielou JY. Phase II trial of 5- fluorouracil (5-FU) and recombinant alpha interferon (RIFN) (INTRON A) in metastatic, previously untreated colorectal cancer (CRC). Proc ASCO 1991; 10:422.

    Google Scholar 

  46. John W, Neef I, Smith M. 5-fluorouracil (5-FU) and interferon- alpha (IFN) in advanced colon cancer: the University of Kentucky experience. Proc ASCO 1992; 11:570.

    Google Scholar 

  47. Dufour P, Husseini F, Cure P. Randomized study of 5- fluorouracil (5-FU) versus 5-FU + alpha 2a interferon (IFN) for metastatic colorectal carcinoma (MCRC). Proc ASCO 1992; 11:583.

    Google Scholar 

  48. York M, Greco FA, Einhorn 1. A randomized phase III trial comparing 5-FU with or without interferon alpha-2a for advanced colorectal cancer. Froc ASCO 1993; 12:200 (Abstr 590).

    Google Scholar 

  49. Hill M, Norman A, Cunningham D. Royal Marsden phase III trial of fluorouracil with or without interferon alpha-2b in advanced colorectal cancer. J Clin Oncol 1995; 13:1297–302

    PubMed  CAS  Google Scholar 

  50. Grem JL, McAtee N, Murphy RF et al. A pilot study of interferon alpha-2a in combination with fluorouracil plus high dose leucovorin in metastatic gastrointestinal carcinoma. J Clin Oncol 1991; 9:1811–1820.

    PubMed  CAS  Google Scholar 

  51. Piedbois P, Gimonet JF, Fenilhade F et al. 5-FU, folinic acid and alpha-2a interferon combination in advanced gastrointestinal cancer. Proc ASCO 1991; 10:430.

    Google Scholar 

  52. Taylor C, Modiano M, Alberts D et al. Combination therapy with 5-fluorouracil (5-FU), leucovorin (LCV) and interferon-alpha (IFN-alpha) in patients with adenocarcinoma. Proc ASCO 1991; 10:432.

    Google Scholar 

  53. Punt CJA, de Mulder PHM, Burghouts JM. A phase I-II study of high-dose 5-fluorouracil (5-FU), leucovorin (LV) and alpha interferon (alpha-IFN) in patients with advanced colorectal cancer. Proc ASCO 1991; 10:465.

    Google Scholar 

  54. Inoshita G, Yalavarthi P, Murthy S. Phase I trial of 5-FU, leucovorin (LV) and IFN -alpha 2a in metastatic colorectal cancer. Proc ASCO 1991; 10:475.

    Google Scholar 

  55. Kohne-Wompner CH, Schmoll HI, Hiddemann Wet al. 5- fluorouracil (5-FU), leucovorin (LV), alpha-2b interferon (IFN) in advanced colorectal cancer (CC): a phase I-II study. Proc ASCO 1991; 10:503.

    Google Scholar 

  56. Labianca R, Pancera G, Tedeschi 1. High dose alfa-2b interferon + folinic acid in the modulation of 5-fluorouraciL A phase II study in advanced colorectal cancer with evidence of an unfavorable cost/benefit ratio. Tumori 1992; 78:32.

    PubMed  CAS  Google Scholar 

  57. Cascinu S, Fedeli A, Luzi Fedeli S. Double biochemical modulation of 5-fluorouracil by leucovorin and cyclic low dose interferon alpha 2b in advanced colorectal cancer patients. Ann Oncol 1992; 3:489

    PubMed  CAS  Google Scholar 

  58. Labianca R, Giaccon G, Pancera G. Low dose alpha 2b interferon (IFN) + folinic acid (FA) + 5-fluorouracil (5-FU) in advanced colorectal cancer (ACC): a phase II study of GISCAD (Italian Group for the Study of Gastrointestinal Cancer). Proc ASCO 1992; 11:523

    Google Scholar 

  59. Moore MJ, Kaizer L, Erlichman C. A phase II clinical and pharmacological study of 5-fluorouracil (5-FU) + leucovorin + interferon in advanced colorectal cancer. Proc ASCO 1992; 11:548.

    Google Scholar 

  60. Van Hazel GA, Buck M, Byrne MJ. Phase II study of the combination of 5-fluorouracil (5-FU), folinic acid (FA) and alpha interferon (IFN) in metastatic colorectal adenocarcinoma cancer (CC). Proc ASCO 1992; 11:594.

    Google Scholar 

  61. Recchia F, Nuzzo A, Lombardo M. 5-fluorouracil (5-FU) and high dose folinic acid (hdFA) chemotherapy (CT) with or without alpha 2b interferon (IFN) in advanced colorectal cancer (ACC). Preliminary report of a randomized trial Proc ASCO 1992; 11:461.

    Google Scholar 

  62. Brunetti I, Falcone A, Bertuccelli M. Double 5-fluorouracil (5-FU) modulation with folinic acid (FA) and recombinant alpha 2b interferon (IFN) in patients with metastatic colorectal carcinoma. Proc ASCO 1992; 11:514.

    Google Scholar 

  63. Schmoll HJ, Kohne-Wompner CH, Hiddemann W. Bolus 5- fluorouracil (FU), folinic acid (FA) and alpha-2b Interferon (IFN) in advanced colorectal cancer (CRC): a multicenter phase II triaL Proc ASCO 1992; 11:535.

    Google Scholar 

  64. Cortesi E, D’ Aprile M, Di Palma M. Advanced colorectal cancer: a phase II study chemoimmunotherapy with IFN alpha 2b + 5-FU c.l. or 5-FU + FA. Proc ASCO 1992; 11:545.

    Google Scholar 

  65. Lembersky B, Koff H, Miketic L et al. Phase II trial of 5- fluorouracil (FU), leucovorin (LV) and interferon alpha-2b (IFN) in the treatment of metastatic colorectal cancer (CRC). Froc ASCO 1992; 11:559.

    Google Scholar 

  66. Kreuser ED, Hilgenfeld RU, Matthias M. Final update on a phase II trial of interferon alpha-2b with folinic acid and 4- hour infusion of 5-fluorouracil in advanced colorectal carcinoma. Proc ASCO 1992; 11:581.

    Google Scholar 

  67. Grem JL, Jordan R, Robson M. A phase II study of interferon alpha-2a in combination with 5-fluorouracil and leucovorin in advanced colorectal cancer. Proc ASCO 1993; 12:600

    Google Scholar 

  68. Corfu-A study group. Phase III randomized study of two combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oneal 1995; 13:921–928.

    Google Scholar 

  69. Fujii S, Okuda H, Toide H. Studies on the fate ofFT-207, an antitumor agent. Absorption, tissue distribution, and excretion. Pharmacokinetics 1974; 8:589–595.

    CAS  Google Scholar 

  70. Mukherjee K, Heidelberger C. Studies on fluorinated pyrimidines. IX. The degradation of 5-fluorouracil-6-C. 14 J Bioi Chern 1960; 235:433–437.

    CAS  Google Scholar 

  71. Taguchi T, Hanano Y, Jikuya K, Fujii S. Effect of uracil on the antitumor activity of ftorafur. Jpn J Cancer Chemother 1978; 5:1161–1165.

    CAS  Google Scholar 

  72. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT Phase II studies. Cancer Chemother Pharmacol 1988; 22:333–338.

    Article  PubMed  CAS  Google Scholar 

  73. Ikenaka K, Shirasaka T, Kitano S. Effect of uracil on metabolism of 5-fluorouracil in vitro. Gann 1979; 70:353–359.

    CAS  Google Scholar 

  74. Ho DH, Covington WP, Pazdur R et al. Clinical pharmacology of combined oral uracil and ftorafur. Drug Metab Dispos 1992; 20:936–940.

    CAS  Google Scholar 

  75. Au JL, Sadee W. Activation offtorafur [R,S-I-(tetrahydro- 2-furanyl)-5-fluorouracill to 5-fluorouracil and gammabutyrolactone. Cancer Res 1980; 40:2814–2819.

    PubMed  CAS  Google Scholar 

  76. El Sayed YM, Sadee W. Metabolic activation of R,S-I(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) to 5- fluorouracil by soluble enzymes. Cancer Res 1983; 43:4039–4044.

    PubMed  CAS  Google Scholar 

  77. Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV, Markowitz AB, Abbruzzese JL, Bready B, Levin B. Phase II trial of uracil and tegafur plus oral leucorovin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994; 12:2296–2300.

    PubMed  CAS  Google Scholar 

  78. Saltz La, Leichman CG, Young CW, Muggia FM, Conti JA, Spies T, Jeffers S, Leichman LP. A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucorovin. Cancer 1995; 75:782–785.

    Article  PubMed  CAS  Google Scholar 

  79. Bollag W, Hartmann HR. Tumor inhibitory effects of a new fluorouracil derivative: 5-deoxy-5-fluorouridine. Eur J Cancer 1979; 16:427–432.

    Article  Google Scholar 

  80. Alberto P, Mermillod B, Germano G et al. Randomized comparison of doxifluorouridine and fluorouracil in colorectal carcinoma. Eur J Cancer (Clin Oncol) 1988; 24:559–563.

    Article  CAS  Google Scholar 

  81. Trave F, Canobbio L, Lai-Sim Au J et al. Role of administration route in the therapeutic efficacy of doxifluorouridine. J Natl Cancer Inst 1987; 78:527–532.

    CAS  Google Scholar 

  82. Y oshimori K, Hasegawa K. Study on efficacy and safety of 5-deoxy-5-fluorouridine (5’-dFUR) with intermittent administration. Prog Antimicrob Anticancer Chemother 1987; 3:493–495.

    Google Scholar 

  83. Alberto P, Winkelmann JJ, Pashoud N et al. Phase I study of oral doxifluridine using two schedules. Eur J Cancer (Clin Oncol) 1989; 25:905–908.

    Article  CAS  Google Scholar 

  84. Bajetta E, Colleoni M, Di Bartolomeo M. Doxifluridine (dFUR) and leucovorin: an oral treatment combination in advanced colorectal cancer. J Clin Oncol 1995; 13:2613–2619.

    PubMed  CAS  Google Scholar 

  85. Jones TR, Calvert AH, Jackman AL. A potent antitumor quinazoline inhibitor of thymidylate synthase: synthesis, biological properties and therapeutic results in mice. Eur J Cancer 1981; 17:11–19.

    Article  CAS  Google Scholar 

  86. Jones TR, Thornton TJ, Flinn A. Quinazoline antifolates inhibiting thymidylate synthase: 2-desamino derivates with enhanced solubility and potency. J Med Chem 1989; 32:847–852.

    Article  PubMed  CAS  Google Scholar 

  87. Hughes LR, Jackman AL, Oldfield J. Quinazoline antifolate thymidylate synthase inhibitors: alkyl, substituted alkyl, and aryl substituents in the C2 positions. J Med Chem 1990; 33:3060–3067.

    Article  PubMed  CAS  Google Scholar 

  88. Jackman AL, Taylor GA, O’Connor BM. Activity of the thymidylate synthase inhibitor 2-desamino-N°-propargyl- 5,8-dideazafolic acid and related compounds in murine (11210) and human (WIL2) systems in vitro and in 11210 in vivo. Cancer Res 1990; 50:5212–5218.

    CAS  Google Scholar 

  89. Jackman AL, Marsham PR, Moran RG, Kimbell R, O’Connor BM, Hughes LR, Calvert AH. Thymidylate synthase inhibitors: the in vitro activity of a series of heterocyclic benzoyl ring modified 2-desamino-2-methyl-NI0-substituted-5,8-dideazafolates. Adv Regul 1991; 31:13–27.

    Article  CAS  Google Scholar 

  90. Jackman AL, Brown M, Kelland L, Gibson W, Abel G, Boyle FT, Judson I. Proc AACR 1991; 32:326.

    Google Scholar 

  91. Jodrell DI, Newell DR, Calvete JA, Stephens TC, Calvert AH. Pharmacokinetic and toxicity studies with the novel quinazoline thymidylate synthase inhibitor, D1694. Proc AACR 1990; 31:341

    Google Scholar 

  92. Judson I, Clarke S, Ward J, Planting A, Verweii J, M de Boer, Spiers J, Smith R, Sutcliffe F. A phase I trial of the thymidylate synthase inhibitor ICI 01694. Ann Oncol 1992 (Suppl 5; Abstr 201); 3:51.

    Google Scholar 

  93. Sorensen JM, Jordan E, Grem JL et al. Phase I trial of ZD1694 (‘Tomudex’), a direct inhibitor of thymidylate synthase. Ann Oncol 5: 1994 (Suppl 5; Abstr 241).

    Google Scholar 

  94. Zalcberg JR, Cunningham D, Van Custem E et al. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 1996; 14(3):716–729.

    PubMed  CAS  Google Scholar 

  95. Cunningham D, Zalcberg JR, Rath U, Olver I, Van Custem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G, 139 Azab M, Seymour L, Lowery K and the Tomudex Colorectal Cancer Study Group. Tomudex (ZD1694): results of a randomized trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 1995; 31(12):1945–1954.

    Article  Google Scholar 

  96. Wall ME, Wani MC, Cook CE Plant anti-tumor agents. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibition from Camp to theca acuminata. J Am Chem Soc 1966; 88:3888–3890.

    Article  CAS  Google Scholar 

  97. Kawato Y, Aonima M, Hirota Y. Intracellular roles of SN- 38, a metabolite of the camptothecin derivative CPT-II, in the antitumor effect of CPT-11. Cancer Res 1991; 51:4187–4191.

    PubMed  CAS  Google Scholar 

  98. Tanizawa A, Fujimori A, Fujimori Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994; 86:836–842.

    CAS  Google Scholar 

  99. Shimada Y, Rothenberg M, Hilsenbeck SG. Activity of CPT- 11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs 1994; 5:202–206.

    Article  CAS  Google Scholar 

  100. Funakoshi S, Aiba K, Shibata H. Enhanced antitumor activity of SN-38, an active metabolite of CPT-11, and 5- fluorouracil combination for human colorectal cancer cell lines. ProcASCO 1994; 12:1607–1611.

    Google Scholar 

  101. Abigerges D, Chabot GG, Armand J. Phase 1 and pharmacologic studies of the camptothecin analogue irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13:210–221.

    PubMed  CAS  Google Scholar 

  102. Abigerges D, Armand JP, Chabot GG. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994; 86:446–449.

    Article  PubMed  CAS  Google Scholar 

  103. Shimada Y, Yashino M, Wakui A. Phase II studyofCPT-11, a new camptothecin derivative, in metastatic colorectal cancer J Clin Oncol 1993; 11:909–913.

    PubMed  CAS  Google Scholar 

  104. Conti JA, Kemeny N, Saltz L, Irinotecan (CPT-11) is an active agent in untreated patients with metastatic colorectal cancer (CRC). Proc ASCO 1994; 13:195.

    Google Scholar 

  105. Pitot HC, Wender D, O’Connell MJ. A phase II trial of CPT- 11 (irinotecan) in patients with metastatic colorectal carcinoma: A North Central Treatment Group (NCCTG) study. Proc ASCO 1994; 13:197.

    Google Scholar 

  106. Rothenberg ML, Eckardt JR, Burris HA III. Irinotecan (CPT-11) as second line therapy for PTS with 5-FU-refractory colorectal cancer. Proc ASCO 1994; 13:198.

    Google Scholar 

  107. Rougier P, Bugat R, Brunet P. Clinical efficacy of CPT-11 in patients with inoperable advanced colorectal cancer (CRC): Results of a multicentric open phase II study. 5th International Congress of Anti-cancer Chemotherapy, Paris, France, 31 January-3 February 1995.

    Google Scholar 

  108. Bugat R CPT-11 in the treatment of colorectal cancer (CRC): Safety profile. 5th International Congress of Anticancer Chemotherapy, Paris, France, 31 January-3 February 1995.

    Google Scholar 

  109. Shimada Y, Sasaki Y, Sugano K. Combination phase I study of CPT -11 (irinotecan) combined with continuous infusion 5-fluorouracil (5-FU) in metastatic colorectal cancer Proc ASCO 1993; 12:196.

    Google Scholar 

  110. Kidani Y, Noji M, Tashiro T. Antitumor Activity of platinum (II) complexes of 1,2-diaminocyclohexane isomers. 1980; 71:637–643.

    CAS  Google Scholar 

  111. J ennerwein MM, Eastman A, Khokhar AR. The role of DNA repair in resistance of 11210 cells to isomeric 1,2- diaminocyclohexane platinum(II) complexes. Chem-Biol Interactions 1989; 70:39–49.

    Article  CAS  Google Scholar 

  112. Silvestro L, Anal H, Sommer F, Trincal G, Tapiero H. Comparative effects of a new platinum analog (trans-I-l,2- diaminocyclohexane oxalatoplatinum; L-OHP) with CDDP on various cells: Correlation with intracellular accumulation. 3 International Conference Anticancer Research, October 1990.

    Google Scholar 

  113. Mathé G, Kidani Y, Noji M, Maral R, Bourut C, Chenu E. Antitumor activity of L-ORP in mice. Cancer Lett 1985; 27:135–143.

    Article  PubMed  Google Scholar 

  114. Machover D, Diaz-RubioE, de Gramont A. Two consecutive phase II studies of oxaliplatin (I-ORP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7:95–98.

    PubMed  CAS  Google Scholar 

  115. Diaz-Rubio E, Zaniboni A, Gastiaburu J. Phase II multicentrc trial of chemotherapy in metastatic colorectal carcinoma (MCRC). Proc ASCO 1996; 15:207 (Abstr 468).

    Google Scholar 

  116. Levi F, Perpoint B, Garufi C et al. Oxaliplatin activity against metastatic colorectal cancer: a phase II study of 5-day continuous venous infusion at circadian-rhythm modulated rate. Eur J Cancer 1993; 29A:1284–1293.

    Google Scholar 

  117. De Gramont A, Gastiaburu J, Tournigand C et al. Oxaliplatin with high dose folinic acid and 5-fluorouracil 48 h infusion in pretreated metastatic colorectal cancer. Proc ASCO 1994; 13: Abstract 666.

    Google Scholar 

  118. Levi F, Misset JL, Brienza S et al. A chronopharmacologic Phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. Cancer 1992; 69:893–900.

    Article  PubMed  CAS  Google Scholar 

  119. Wilson JD, Braunwald E, Isselbacher KJ, Petersdorf RG, Martin JB, Fauci AS, Root RK. Harrison’s Principles of Internal Medicine, 12th edn. Neoplasm of the Liver. Metastatic Tumors, 1991: 1350–1352.

    Google Scholar 

  120. Luporini G, Labianca R, Locatelli MC, Beretta G. Chemioterapia Locoregionale e Sistemica dei Tumori Epatici. ‘I Tumori Gastroenterici’, 1984: 303–315. Milan, CEA Casa Editrice Ambrosiana.

    Google Scholar 

  121. Chevallier B, Fumoleau P, Kerbrat P et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a Phase II trial of the clinical screening cooperative group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995; 13(2):314–322

    CAS  Google Scholar 

Download references

Authors
  1. Roberto Labianca
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppe Dallavalle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Adelaide Pessi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giuseppina Zamparelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgery, University of Edinburgh, Royal Infirmary, Lauriston Place, EH3 9YW, Edinburgh, UK

    O. J. Garden (Professor of Hepatobiliary Surgery) (Professor of Hepatobiliary Surgery)

  2. Professorial Department of Surgery, Nottingham City Hospital, Hucknall Road, NG5 1PB, Nottingham, UK

    J. G. Geraghty (Consultant Surgeon) (Consultant Surgeon)

  3. Mayo Clinic, 200 First Street SW, MN 55905, Rochester, Minnesota, USA

    D. M. Nagorney (Professor of Surgery) (Professor of Surgery)

  4. European Institute of Oncology, Via Ripamonti 435, 20133, Milan, Italy

    R. A. Audisio (Deputy Director of General Surgery) (Deputy Director of General Surgery)

  5. Department of Surgical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy

    H. S. Stoldt (Consultant Surgeon) (Consultant Surgeon)

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag London Limited

About this chapter

Cite this chapter

Labianca, R., Dallavalle, G., Pessi, M.A., Zamparelli, G. (1998). Systemic Therapy. In: Garden, O.J., Geraghty, J.G., Nagorney, D.M., Audisio, R.A., Stoldt, H.S. (eds) Liver Metastases. Springer, London. https://doi.org/10.1007/978-1-4471-1506-9_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-1506-9_10

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-1508-3

  • Online ISBN: 978-1-4471-1506-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation